Clinical trials: Nerve Sheath Tumors
Amputation Neuroma
The Efficacy of Preventive Regenerative Peripheral Nerve Interface(RPNI) Reconstruction in Amputees
The trial will be carried out in Peking University People's Hospital. The whole trial will last 3 years. Amputees from orthopedics and vascular surgery will be distributed into two groups randomly and receive different treatments…
- Trial name
- NCT05554900
- Testing
- preventive regenerative peripheral nerve interface reconstruction
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Peking University People's Hospital
Neurofibromatosis Type 1
Analysis of Peripheral Nerve Sheath Tumors (PNSTs) in Neurofibromatosis Type 1 (NF1) Patients
Neurofibromatosis type 1 (NF1) is a frequent, autosomal dominant disorder caused by heterozygous mutations (intragenic or microdeletion) of the NF1 tumor suppressor gene (chr.17q11.2).
- Trial name
- NCT01218139
- Where
- Belgium
- Volunteers
- 50 people
- Sponsor
- KU Leuven
Childhood Malignant Fibrous Histiocytoma of Bone, Sarcoma
Celecoxib and Radiation Therapy in Treating Patients With Stage II or Stage III Soft Tissue Sarcoma of the Arm, Hand, Leg, or Foot That Has Been Removed by Surgery
RATIONALE: Celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Trial name
- NCT00450736
- Testing
- celecoxib, adjuvant therapy, radiation therapy
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Miami
Pain Management, Quality of Life
Neuroma-Associated Pain Management After Combat-Related Trauma in Ukraine
This multicenter interventional study in Ukraine is designed to compare the effectiveness of cryoablation and radiofrequency ablation in managing neuroma-associated pain following combat-related trauma.
- Conditions
- Pain Management, Quality of Life, Neuroma, Functional Outcome
- Trial name
- NAP-C/R (NCT07416448)
- Testing
- cryoablation, Radiofrequency ablation alone
- Where
- Ukraine
- Volunteers
- 100 people
- Sponsor
- Ukrainian Society of Regional Anesthesia and Pain Therapy
Vestibular Schwannoma, Neurinoma, Acoustic
Evolution of Vestibular Function After Treatment of a Vestibular Schwannoma by Gamma-knife Radio-surgery
The purpose of this study is to evaluate the vestibular effects of gamma-knife radiosurgery, as part of the treatment of vestibular schwannoma.
- Conditions
- Vestibular Schwannoma, Neurinoma, Acoustic, Acoustic Neuroma
- Trial name
- EVERS (NCT06112509)
- Testing
- Vestibular exam
- Where
- France
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Neuroma
Regenerative Peripheral Nerve Interfaces to Treat Painful Digit and Hand Neuromas After Amputation
This study is being done to demonstrate the effectiveness of Regenerative Peripheral Nerve Interfaces (RPNI) surgery in treating symptomatic neuromas of the hand and digits following amputation compared to standard of care using…
- Trial name
- NCT05008185
- Testing
- Regenerative Peripheral Nerve Interface (RPNI) surgery, Traction Neurectomy
- Where
- 2 sites in United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Medstar Health Research Institute
Sarcoma
PET CT as Predictor of Response in Preoperative Chemotherapy for Soft Tissue Sarcoma
RATIONALE: Diagnostic procedures, such as positron emission tomography (PET) scan and computated tomography (CT) scan, may help doctors predict a patient's response to treatment and may help plan the best treatment.
- Trial name
- NCT00346125
- Testing
- pegfilgrastim, doxorubicin hydrochloride, ifosfamide
- Where
- 2 sites in United States
- Volunteers
- 70 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Neuroma
Evaluation of NEUROCAP® In the Treatment of Symptomatic Neuroma
PROSPECTIVE COHORT EVALUATION OF NEUROCAP® In the Treatment of symptomatic Neuroma (PROTECT Neuro) This post-market surveillance study is conducted to provide post market surveillance information regarding long-term performance…
- Trial name
- NCT02993276
- Testing
- Neurocap®
- Where
- 16 sites in United States, France and 5 more
- Volunteers
- 73 people
- Sponsor
- Polyganics BV
Symptomatic Neuroma, Amputation
Tolerability and Feasibility Pilot Clinical Study of a Large-Diameter Nerve Cap for Protecting and Preserving Terminated Nerve Ends
This pilot study evaluates the tolerability and feasibility of the Axoguard Large-Diameter Nerve Cap (sizes 5-7 mm) for protecting and preserving terminated nerve endings after limb trauma or amputation when immediate attention…
- Conditions
- Symptomatic Neuroma, Amputation, Chronic Nerve Pain
- Trial name
- REPOSE-XL℠ (NCT04865679)
- Testing
- Axoguard Nerve Cap®
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Axogen Corporation
Vestibular Schwannoma, Vestibular Function Disorder
Role of Psychiatric Profile in Prehabituated Patients After Vestibular Schwannoma Surgery
The aim of this study is to assess effect of psychiatric profile on visual sensitivity and overall health status in patients who underwent surgery for vestibular schwannoma and were prehabituated by chemical vestibular ablation.
- Trial name
- NCT03638310
- Testing
- intratympanic application of gentamicin, microsurgical removal of vestibular schwannoma
- Where
- Czechia
- Volunteers
- 37 people
- Sponsor
- Charles University, Czech Republic
Neurofibromatoses
The Neurofibromatosis-associated Tumor Biobank
Neurofibromatosis-associated Tumor is very rare bone tumor. The investigator set up the biobank to ensure every patient has the chance to participate in future research
- Trial name
- NCT03359304
- Volunteers
- 300 people
- Sponsor
- Ren tingting
Neurofibromatosis 1 (NF1), Executive Function (Cognition)
Cognitive Intervention for Children and Adolescents With NF1
Psychological interventions have been shown to be effective for managing cognitive and mental health challenges in different patient populations.
- Conditions
- Neurofibromatosis 1 (NF1), Executive Function (Cognition), Cognitive Intervention
- Trial name
- NCT07869914
- Testing
- Unstuck and On Target!
- Volunteers
- 60 people
- Sponsor
- The Hospital for Sick Children
Neurofibromatosis Type 1, Learning Disability
Interventions for Reading Disabilities in NF1
Neurofibromatosis Type 1 (NF1) is a common genetic disorder that is associated with a four times greater risk of learning disabilities, including reading disabilities, and a deficiency of neurofibromin - a protein important in a…
- Conditions
- Neurofibromatosis Type 1, Learning Disability, Reading Disability, NF1
- Trial name
- NCT02964884
- Testing
- Lovastatin, reading tutoring intervention
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University
Neurofibromatosis Type 1
Effects of Physical Training on Bone and Muscle Quality, Muscle Strength, and Motor Coordination in Children With NF1
A physical training program will improve quality of life, participation in physical activity, motor coordination, muscle strength, and bone and muscle strength in children with neurofibromatosis type 1.
- Trial name
- NCT01058330
- Testing
- Plyometric training program
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Shriners Hospitals for Children
Neurofibromatosis 2, Vestibular Schwannoma
Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors
In this research study the researchers want to learn more about the effects (both good and bad) the study drug selumetinib has on participants with neurofibromatosis type II (NF2) related tumor.
- Conditions
- Neurofibromatosis 2, Vestibular Schwannoma, Meningioma, Ependymoma
- Trial name
- SEL-TH-1601 (NCT03095248)
- Testing
- Selumetinib
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Neurocutaneous Syndromes, Neurofibromatosis Type 1 (NF1)
Precision Medicine for Neurocutaneous Syndromes in Western China
The goal of this observational study (retrospective multicenter cohort study) is to learn if precision medicine approaches-including genetic testing, targeted drugs, and coordinated care from multiple specialists-can improve…
- Conditions
- Neurocutaneous Syndromes, Neurofibromatosis Type 1 (NF1), Tuberous Sclerosis Complex (TSC), Sturge-Weber Syndrome (SWS)
- Trial name
- NCT07327164
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- West China Hospital
Neuroma
Botulinum Toxin Type A for Neuroma Pain
The purpose of this study is to determine if botulinum toxin type A (Btx-A) is an effective treatment for painful neuromas. The ideal therapy for painful neuromas would be effective, non-addictive, safe, localized, and…
- Trial name
- NCT01374191
- Testing
- onabotulinum toxin type-A, 2nd phase - onabotulinum toxin type-A
- Where
- United States
- Sponsor
- Southern Illinois University
Sarcoma, Neoplasms, Connective and Soft Tissue
Autologous Dendritic Cell Vaccine in Patients With Soft Tissue Sarcoma
The purpose of this study is to achieving a six-month progression free survival (PFS) of patients receiving autologous dendritic cell vaccine (ADKV) loaded with allogeneic tumor lysate expression of cancer-testis antigens (CTA)…
- Trial name
- ADCVCTAST (NCT01883518)
- Testing
- Autologous dendritic cell vaccine
- Where
- Russia
- Volunteers
- 48 people
- Sponsor
- N.N. Petrov National Medical Research Center of Oncology
NF type1 With Inoperable Plexiform Neurofibromas
An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1
This will be an open-label, single-arm, multicenter intermediate access protocol which provides treatment access to selumetinib for eligible patients with neurofibromatosis type 1 (NF1) who have inoperable…
- Trial name
- NCT03259633
- Testing
- Selumetinib
- Where
- United States
- Sponsor
- AstraZeneca
Neoplasms, Adenomatous Polyposis Coli
Clinical Sequencing of Cancer and Tissue Repository: OncoGenomics
Background: Saliva, blood, tissue, and cancer contain DNA. DNA makes the "instruction book" for the cells in the body. Cancer is caused by changes in DNA that affect cell function.
- Conditions
- Neoplasms, Adenomatous Polyposis Coli, Neurofibroma, Plexiform, Myelodysplastic Syndromes
- Trial name
- NCT03027401
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)